Q & A

Read the latest PLC CEO interviews. CEO’s from UK listed PLC’s, Analysts and Fund Managers answering questions about their business.

Pantheon International Analyst Q&A: Significant long-term out-performance (LON:PIN)

Pantheon International (LON:PIN) is the topic of conversation when Hardman and Co’s Analyst Mark Thomas caught up with DirectorsTalk for an exclusive interview. Q1: You titled your piece “History of..

Hardide Q&A Record revenue & a strong start to new financial year (LON:HDD)

Hardide (LON:HDD) Chief Executive Officer Philip Kirkham caught up with DirectorsTalk for an exclusive interview to discuss record revenues, the broadening of customer & sector base, new bigger premises and..

Palace Capital Analyst Q&A with Hardman & Co (LON:PCA)

Palace Capital (LON:PCA) is the topic of conversation when Hardman and Co’s Analyst Mike Foster caught up with DirectorsTalk for an exclusive interview. Q1: PCA has reported results, what is..

Non-Standard Finance Analyst Q&A (LON:NSF)

Non-Standard Finance (LON:NSF) is the topic of conversation when Hardman and Co’s Analyst Mark Thomas caught up with DirectorsTalk for an exclusive interview. Q1: Non-Standard Finance had a severe share..

ImmuPharma Q&A: More positive news will continue to strengthen share price (LON:IMM)

ImmuPharma's Tim McCarthy discusses their licencing & development agreement with Avion, the Lanstead deal and the key investment points for investing in IMM in this exclusive interview with DirectorsTalk...

Gresham House Strategic MD Q&A with Graham Bird (LON:GHS)

Gresham House Strategic (LON:GHS) Managing Director Graham Bird caught up with DirectorsTalk for an exclusive interview to discuss financial and investment management highlights, post period performance and the outlook for..

Premier Miton Investors Q&A with Head of Equities Gervais Williams (LON:PMI)

Premier Miton Investors (LON:PMI) Head of Equities Gervais Williams caught up with DirectorsTalk for an exclusive interview to discuss Morgan Stanley’s view on UK equities, how attractive the FTSE Small..

Sativa Group Q&A: New appointments, medicinal cannabis licence & admission to AIM (NEX:SATI)

Sativa Group (NEX:SATI) Chief Executive Officer Henry Lees-Buckley caught up with DirectorsTalk for an exclusive interview to discuss the new appointments in the Group, the progress of the cannabis cultivation..

Cambria Automobiles Q&A “Results are very impressive” (LON:CAMB)

Cambria Automobiles (LON:CAMB) is the topic of conversation when Zeus Capital’s Head of Research Mike Allen caught up with DirectorsTalk for an exclusive interview. Q1: Cambria Automobiles has released full..

TT Electronics Q&A: Good performance to continue into 2020 (LON:TTG)

TT Electronics (LON:TTG) Chief Executive Officer Richard Tyson caught up with DirectorsTalk for an exclusive interview to discuss the recent trading update, good visibility going forward, the Excelitas acquisition and..

Touchstone Exploration Q&A Production to double from existing production base (LON:TXP)

Touchstone Exploration (LON:TXP) Chief Executive Officer Paul Baay caught up with DirectorsTalk for an exclusive interview to discuss the test results at their COHO well, what’s next on the exploration..

NQ Minerals Q&A with new Chairman David Lenigas (NEX:NQMI)

NQ Minerals (NEX:NQMI) Chairman David Lenigas caught up with DirectorsTalk for an exclusive interview to discuss his new role as Chairman, what investors can expect over the coming months and..

Jubilee Metals Group Q&A “Tremendous growth in earnings” (LON:JLP)

Jubilee Metals Group (LON:JLP) Chief Executive Officer Leon Coetzer caught up with DirectorsTalk for an exclusive interview to discuss their results for the year ended 30 June, growth in earnings..

Advanced Oncotherapy Analyst Q&A with Dr Martin Hall (LON:AVO)

Advanced Oncotherapy (LON:AVO) is the topic of conversation when Hardman and Co’s Head of Life Sciences Dr Martin Hall caught up with DirectorsTalk for an exclusive interview. Q1: You recently..

Morses Club Analyst Q&A “Clear customer-demand-driven strategy”

Morses Club (LON:MCL) is the topic of conversation when Hardman and Co’s Financial Analyst Mark Thomas caught up with DirectorsTalk for an exclusive interview. Q1: What lessons did you learn..

Arbuthnot Banking Group Q&A Analyst notes continued strong franchise growth (LON:ARBB)

Arbuthnot Banking Group (LON:ARBB) is the topic of conversation when Hardman and Co’s Financial Analyst Mark Thomas caught up with DirectorsTalk for an exclusive interview. Q1: What did Arbuthnot Banking..

Genedrive Analyst anticipating accelerated news flow (LON:GDR)

Genedrive (LON:GDR) is the topic of conversation when Hardman and Co’s Analyst Dr Dorothea Hill caught up with DirectorsTalk for an exclusive interview. Q1: You recently released a note explaining that..

Q&A with Avacta Group CEO Alastair Smith (LON:AVCT)

Avacta Group (LON:AVCT) Chief Executive Officer Alastair Smith caught up with DirectorsTalk for an exclusive interview to discuss their agreement with ADC Therapeutics, the Phase I AVA6000 trial, commercial opportunities,..

Inchcape Analyst Q&A wth Zeus Capital (LON:INCH)

Inchcape (LON:INCH) is the topic of conversation when Zeus Capital’s Head of Research Mike Allen caught up with DirectorsTalk for an exclusive interview. Q1: Inchcape, you’ve just put a new..

Vordere Q&A with CEO Nicholas Hofgren (LON:VOR)

Vordere (LON:VOR) Chief Executive Officer Nicholas Hofgren caught up with DirectorsTalk for an exclusive interview to discuss their latest acquisition in Brazil, the background behind next week’s GM, advice to..

Search

Funds

Q & A

ImmuPharma Q&A: More positive news will continue to strengthen share price (LON:IMM)

ImmuPharma's Tim McCarthy discusses their licencing & development agreement with Avion, the Lanstead deal and the key investment points for investing in IMM in this exclusive interview with DirectorsTalk...
Search

Funds

Q & A

FTSE 100

Funds